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Novel Vitiligo Susceptibility Loci on Chromosomes 7
(AIS2) and 8 (AIS3), Conﬁrmation of SLEV1
on Chromosome 17, and Their Roles
in an Autoimmune Diathesis
To the Editor:
Generalized vitiligo (MIM 193200) is a common ac-
quired disorder in which patches of white skin and over-
lying hair result from loss of pigment-forming melano-
cytes (reviewed in Bolognia et al. [1998], Kovacs [1998],
and Hann and Nordlund [2000]), apparently because of
a noninﬂammatory, T cell autoimmune response (re-
viewed in Ongenae et al. [2003]). Vitiligo occurs in
0.38% of whites (Howitz et al. 1977) and, in 23% of
cases, is associated with other autoimmune disorders,
particularly including autoimmune thyroid disease, per-
nicious anemia, systemic lupus erythematosus, Addison
disease (Alkhateeb et al. 2003), and adult-onset insulin-
dependent diabetes mellitus (our unpublished data). This
complex of associated multiple autoimmune diseases
most likely results from combinations of genes, some
predisposing to an inherited autoimmune diathesis and
others to speciﬁc forms of autoimmune disease. In the
past, the association of various multiple autoimmune
diseases has been termed “autoimmune polyendocrine
syndrome, type 2” (APS2 [MIM 269200]), with a num-
ber of descriptive subcategories, the biological bases for
which are uncertain (reviewed in Betterle et al. [2002]).
Vitiligo is a polygenic, multifactorial disorder (Majum-
der et al. 1988; Nath et al. 1994; Arcos-Burgos et al.
2002; Alkhateeb et al. 2003), with frequent family clus-
tering (Mehta et al. 1973; Carnevale et al. 1980; Goudie
et al. 1983; Hafez et al. 1983; Das et al. 1985;Majumder
et al. 1993; Alkhateeb et al. 2003), and ∼20% of pro-
bands having at least one affected ﬁrst-degree relative
(Alkhateeb et al. 2003). We previously described a ge-
nome scan of 71 white multiplex families with vitiligo,
and we mapped AIS1 (autoimmune susceptibility 1), a
locus in chromosome segment 1p31.3-p32.2 that ap-
parently confers susceptibility to generalized vitiligo and
associated autoimmune disorders, as well as seven ad-
ditional suggestive linkage signals on chromosomes 1,
7, 8, 11, 19, and 22 (Alkhateeb et al. 2002; Fain et al.
2003).
We have now extended this study to a total of 102
white multiplex families with vitiligo, providing substan-
tially increased power for genomewide linkage analysis.
Families were ascertained principally from the Vitiligo
Society (U.K.) and the National Vitiligo Society (U.S.A.),
as described elsewhere (Fain et al. 2003). Phenotypeswere
checked carefully by history, lesion maps, and, in most
cases, physical examination and/or photographs; indi-
viduals for whom the phenotype was at all questionable
were excluded. DNAwas prepared from peripheral blood
by standard methods, and genotyping was performed on
a total of 660 individuals (300 affected with vitiligo;
192 females, 108 males) for 382 autosomal microsat-
ellite markers from the ABI Prism 10-cM Linkage Map-
ping Set LMSv2-MD10, with manual checking of all
genotypes by at least two people to minimize data errors,
as described elsewhere (Fain et al. 2003). Multipoint
nonparametric linkage analyses were performed using
Allegro (Gudbjartsson et al. 2000). Heterogeneity testing
between autoimmune and nonautoimmune families was
performed using a predivided sample test (Morton 1956;
Ott 1999).
As shown in table 1, analysis of the extended 102-
family cohort provides continued strong support forAIS1
at 73.7 cM on chromosome 1p ( ;LODp 5.59 Pp
) (all positions have been updated in accor-.000000279
dance with the deCODE genomemap [Kong et al. 2002]).
In addition, two other signals that previously were only
suggestive now achieve threshold criteria for signiﬁcant
linkage (Lander and Kruglyak 1995). These loci, now
designated “AIS2” at 89.4 cM on chromosome 7
( ; ) and AIS3 at 54.2 cM onLODp 3.73 Pp .0000208
chromosome 8 ( ; ), thus rep-LODp 3.36 Pp .0000418
resent candidates for conﬁrmation by analysis of a rep-
licate family cohort. Our data also provide support for
a locus at 4.3 cM on chromosome 17 ( ;LODp 3.07
), most likely corresponding to SLEV1, aPp .0000852
locus detected in multiplex families with lupus that also
segregate cases of vitiligo (Nath et al. 2001). Three link-
age signals that were suggestive in our previous analysis
of 71 families (Fain et al. 2003)—at 12.2 cM on chro-
mosome 1p, 4.1 cM on 11p, and 107.8 cM on 19q—
fell below the threshold for suggestive linkage at the 102-
family level. However, we detected two new linkage
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Table 1
Suggestive and Signiﬁcant LODs (and P Values) for 71 and 102 Multiplex
White Families with Vitiligo
CHROMOSOME
AND DISTANCE MARKER(S)
LOD (P) IN
71 Familiesa 102 Families
1:
12.2 cM D1S214 2.17 (.000335) NS
73.7 cMb D1S2797-D1S2890 5.56 (.000000282 ) 5.59 (.000000279 )
7:
89.4 cMc D7S669 2.87 (.000131) 3.73 (.0000208)
8:
54.2 cMd D8S505 1.95 (.00135) 3.36 (.0000418)
9:
88.1 cM D9S167-D9S283 NS 2.34 (.000238)
11:
4.1 cM D11S4046-D11S1338 1.93 (.00142) NS
13:
109.4 cM D13S173 NS 2.30 (.000563)
17:
4.3 cMe D17S849-D17S831 NS 3.07 (.0000852)
19:
34.9 cM D19S221-D19S226 2.45 (.000388) 2.62 (.000254)
107.8 cM D19S210 2.31 (.000551) NS
22:
7.7 cM D22S420-D22S539 2.30 (.000561) 2.98 (.000106)
NOTE.—Only linkage signals achieving signiﬁcant ( and/orLOD 3.3 P .000049
[shown in boldface italics]) or suggestive ( and/or ) de novo linkageLOD 1.86 P .0017
thresholds (Terwilliger and Ott 1994; Lander and Kruglyak 1995; Nyholt 2000) are
reported; the signiﬁcant linkage threshold for independent replication (i.e., SLEV1) is
(Lander and Kruglyak 1995). NS denotes not suggestive. Genome positions haveP .01
been updated using the deCODE genome map (Kong et al. 2002) and sequence-based
STS map (National Center for Biotechnology Information). All gene symbols have been
approved by the HUGO gene nomenclature committee.
a Fain et al. 2003.
b AIS1.
c AIS2.
d AIS3.
e SLEV1.
Table 2
Vitiligo-Associated Autoimmune Diseases in the 51 Autoimmunity-
Associated Families
AUTOIMMUNE DISEASE
NO. OF AFFECTED
Families Individuals
Vitiligo 51 221
Autoimmune thyroid disease 46 119
Pernicious anemia 11 19
Adult-onset insulin-dependent diabetes mellitus 10 15
Addison disease 2 2
Systemic lupus erythematosus 1 1
Other autoimmune diseases 38 85
NOTE.—A total of 323 family members reported autoimmune
diseases; some reported more than one autoimmune disease (mean
1.43 autoimmune diagnoses per individual). Not all individuals were
genotyped.
signals that met criteria for suggestive linkage (Lander
and Kruglyak 1995)—at 88.1 cM on chromosome 9q
( ; ) and at 109.4 cM on 13qLODp 2.34 Pp .000238
( ; )—that represent candidatesLODp 2.30 Pp .000563
for follow-up extension and replication linkage studies.
The 102 study families were selected solely on the basis
of having multiplex cases of vitiligo. Nevertheless, half of
the families segregated only vitiligo, whereas the other
half also segregated various others of the vitiligo-associ-
ated autoimmune diseases (autoimmune thyroid disease,
pernicious anemia, lupus, Addison disease, or adult-onset
autoimmune diabetes mellitus) (Alkhateeb et al. 2002)
(table 2). This provided an obvious basis for phenotypic
stratiﬁcation of the 102 families into autoimmunity-as-
sociated versus nonautoimmunity-associated family sub-
groups and analysis of the four a priori signiﬁcant linkage
signals in each subgroup. As shown in table 3, the AIS1,
AIS2, and SLEV1 linkage signals derive principally from
the autoimmunity-associated family subgroup and thus
may predispose to a vitiligo-associated autoimmunity dia-
thesis. Indeed, the AIS1 and SLEV1 LODs increased sub-
stantially on family stratiﬁcation, even though the number
of families was reduced by half. AIS1 was originally
mapped in a large family with vitiligo,Hashimotodisease,
and 21-hydroxylase autoantibody positivity (a preclinical
marker for Addison disease) (Alkhateeb et al. 2002), and
SLEV1 was originally mapped in families segregating lu-
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Table 3
LODs (and P Values) on Phenotypic Stratiﬁcation of 102 Multiplex Families with Vitiligo
into Autoimmunity-Associated and Nonautoimmunity-Associated Family Subgroups
LOCUS
LOD (P) FOR
All Families ( )np 102
Families with
Autoimmunity ( )np 51 Nonautoimmunity ( )np 51
AIS1 5.59 (.000000279) 6.02 (.0000000887) .22 (.158)
AIS2 3.73 (.0000208) 3.24 (.0000836) .67 (.040)
AIS3 3.36 (.0000418) .85 (.024) 2.88 (.000138)
SLEV1 3.07 (.0000852) 4.00 (.00000870) .29 (.125)
pus and vitiligo (Nath et al. 2001), so the derivation of
these linkage signals from the autoimmunity-associated
family subgroup is not unexpected. In contrast, the
AIS3 linkage signal appears to derive principally from
the nonautoimmunity-associated family subgroup. AIS3
may thus predispose to vitiligo per se, rather than to an
autoimmune diathesis, although, of course, the basis of
generalized vitiligo even in these families might still be
autoimmune in nature.
Heterogeneity testing did not quite exclude the pos-
sibility that AIS1 might also contribute to vitiligo sus-
ceptibility in the nonautoimmune families, since the total
LOD score did not decrease signiﬁcantly ( )Pp .084
when the autoimmune and nonautoimmune family sub-
groups are combined, compared with the LOD in the
autoimmune families alone. This was also the case for
AIS2 and AIS3 ( and .192, respectively). ThesePp .362
results suggest the possibility of allelic heterogeneity at
these loci between these two groups of families. How-
ever, for SLEV1, there was a signiﬁcant ( ) de-Pp .018
crease in the LOD score when the autoimmune and non-
autoimmune family subgroups were combined, a result
that suggests linkage to SLEV1 in the autoimmune fami-
lies and nonlinkage in the nonautoimmune families. Fur-
thermore, although SLEV1 was originally detected in
multiplex families with lupus with at least one case of
vitiligo (Nath et al. 2001), there was only a single case
of possible lupus among all of our 51 autoimmune fami-
lies. Thus, linkage to SLEV1 in these families indicates
that SLEV1 confers susceptibility to a broader range of
autoimmune diseases than just lupus and vitiligo.
Our data thus indicate that generalized vitiligo can be
divided into at least two distinct phenotypic subcategories
that apparently involve different loci or alleles. Vitiligo
associated with a speciﬁc constellation of autoimmune
diseases is linked with AIS1, AIS2, and SLEV1, whereas
vitiligo unassociated with other autoimmune diseases is
linked with AIS3. These ﬁndings begin to elucidate the
genetic underpinnings of vitiligo and to dissect the con-
tributions of individual loci to the vitiligo-associated au-
toimmune disease diathesis.
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